is a new NPY derived peptide drug for intravital [eye] injection that already has demonstrated functional improvement of the sight as well as neuroprotection in several in vivo models.
is being prepared for clinical study in patients with retinal detachment as a proof-ofconcept indication.
RP002 and RP003
are additional NPY derived peptide candidate drugs that are being investigated as back-up programs.
is also investigating gene delivery as potential administration of neuroprotective drugs to the eye.